Original Research
Accepted on 06 Feb 2026
CD73 expression as a resistance mechanism in advanced EGFR-mutated non-small cell lung cancer (NSCLC)
in Thoracic Oncology
Frontiers in Oncology
- Frontiers in Oncology
- Thoracic Oncology
- Articles
Type at least 3 characters
1,962 articles
articles
Correction
Published on 06 Feb 2026
Correction: Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2026.1783059
- 194 views
Case Report
Published on 06 Feb 2026
Primary pulmonary histiocytic sarcoma with CNS metastasis: a case report and molecular profiling insights
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2026.1636634
- 286 views
Correction
Accepted on 05 Feb 2026
Correction: TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations
in Thoracic Oncology
Frontiers in Oncology
Review
Published on 05 Feb 2026
The role of antibody-drug conjugates in the treatment of lung cancer
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2026.1757564
- 557 views
Original Research
Published on 04 Feb 2026
Utility of PPO-FEV1%pred in predicting postoperative pulmonary complications after secondary surgery in patients with multiple primary lung cancers
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2026.1747652
- 265 views
Brief Research Report
Accepted on 03 Feb 2026
Association of endocrine immune-related adverse events with progression-free survival in advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors with or without anlotinib
in Thoracic Oncology
Frontiers in Oncology
Case Report
Accepted on 03 Feb 2026
Malignant Triton Tumor with Thoracic Region as the Initial Presentation: A Case Report
in Thoracic Oncology
Frontiers in Oncology
Original Research
Accepted on 02 Feb 2026
COL11A1 Promotes Lung Adenocarcinoma Progression via PI3K/AKT/mTOR Pathway: Mechanistic Insights and Development of a COL11A1-Related Prognostic Signature
in Thoracic Oncology
Frontiers in Oncology
- 151 views
Correction
Accepted on 02 Feb 2026
Factors Associated with Secondary Thoracotomy for Hemostasis Following lung surgery: A Retrospective Analysis
in Thoracic Oncology
Frontiers in Oncology
Original Research
Published on 02 Feb 2026
Identification of candidate biomarker MRPL23 and its prognostic potential in non-small cell lung cancer with emphasis on the squamous cell carcinoma subtype
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2026.1663235
- 407 views
Review
Published on 02 Feb 2026
ROS1-positive non-small cell lung cancer: from genomics to treatment decisions
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2026.1739598
- 562 views
Original Research
Published on 02 Feb 2026
BUB1 promotes lung adenocarcinoma progression by regulating STAT3/GPX4-mediated ferroptosis
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2025.1745238
- 423 views
Original Research
Accepted on 30 Jan 2026
Differences in the expression profiles of m6A-related genes and the prognostic role in immunotherapy for lung adenocarcinoma patients
in Thoracic Oncology
Frontiers in Oncology
- 170 views
Original Research
Accepted on 30 Jan 2026
Composite Patient-Reported Outcomes and Risk Prediction for Overall Survival in Advanced Non-Small Cell Lung Cancer With First-Line Cemiplimab
in Thoracic Oncology
Frontiers in Oncology
- 102 views
Original Research
Accepted on 30 Jan 2026
Cadonilimab (PD-1/CTLA-4 bispecific antibody) combination therapy for Driver Gene-Negative Advanced NSCLC: A Single-Center Retrospective Real-World Study
in Thoracic Oncology
Frontiers in Oncology
- 136 views
Original Research
Accepted on 29 Jan 2026
The STAT3–ZEB1 axis contributes to CCL2-mediated resistance to osimertinib in lung cancer
in Thoracic Oncology
Frontiers in Oncology
Case Report
Published on 29 Jan 2026
Furmonertinib plus pemetrexed in the treatment of EGFR exon 19 deletion lung adenocarcinoma: two case reports
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2026.1709552
- 501 views
Case Report
Published on 29 Jan 2026
Case Report: Complete pathologic response to neoadjuvant immunotherapy-chemotherapy in a patient with RET fusion-positive non-small cell lung cancer
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2026.1730615
- 411 views
Mini Review
Published on 29 Jan 2026
The chick embryo chorioallantoic membrane as an experimental model to study lung cancer
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2026.1758487
- 379 views
Editorial
Accepted on 28 Jan 2026
Editorial: Treatment Response and Resistance to Targeted Therapies for NSCLC
in Thoracic Oncology
Frontiers in Oncology
Systematic Review
Accepted on 28 Jan 2026
ctDNA clearance predicts survival in unresectable EGFR-mutant NSCLC: a meta-analysis
in Thoracic Oncology
Frontiers in Oncology
- 113 views
Original Research
Published on 28 Jan 2026
Shox2 and Rassf1a DNA methylation: diagnostic utility and association with clinical stage, histological progression and gene mutational landscape in lung adenocarcinoma
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2026.1727695
- 338 views
Original Research
Published on 27 Jan 2026
Efficacy of TKIs in non-small cell lung cancer with atypical EGFR p.L747P and p.L747S mutations
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2026.1717191
- 565 views